SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-F_HAB) and atezolizumab in patients with platinum-resistant ovarian cancer.

Authors

Sant P. Chawla

Sarcoma Oncology Center, Santa Monica, CA

Sant P. Chawla , Bo Gao , Carolyn L. Bampton , Brett Hamilton , John K. Cini , Susan Dexter , Richard T. Kenney , Robert Michael Wenham

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT05756907

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS5629)

DOI

10.1200/JCO.2024.42.16_suppl.TPS5629

Abstract #

TPS5629

Poster Bd #

496a

Abstract Disclosures

FEATURED

SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-F_HAB) and atezolizumab in patients with platinum-resistant ovarian cancer.

Authors

Sant P. Chawla

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.